- Home
- PCRX vs NMZ Comparison
PCRX vs NMZ Comparison
Compare PCRX & NMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- NMZ
- Stock Information
- Founded
- PCRX 2006
- NMZ 2003
- Country
- PCRX United States
- NMZ United States
- Employees
- PCRX N/A
- NMZ N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- NMZ Finance/Investors Services
- Sector
- PCRX Health Care
- NMZ Finance
- Exchange
- PCRX Nasdaq
- NMZ Nasdaq
- Market Cap
- PCRX 1.2B
- NMZ 1.2B
- IPO Year
- PCRX 2011
- NMZ N/A
- Fundamental
- Price
- PCRX $26.29
- NMZ $10.39
- Analyst Decision
- PCRX Buy
- NMZ
- Analyst Count
- PCRX 9
- NMZ 0
- Target Price
- PCRX $29.89
- NMZ N/A
- AVG Volume (30 Days)
- PCRX 891.6K
- NMZ 356.8K
- Earning Date
- PCRX 05-08-2025
- NMZ 01-01-0001
- Dividend Yield
- PCRX N/A
- NMZ 5.08%
- EPS Growth
- PCRX N/A
- NMZ N/A
- EPS
- PCRX N/A
- NMZ N/A
- Revenue
- PCRX $702,772,000.00
- NMZ N/A
- Revenue This Year
- PCRX $8.63
- NMZ N/A
- Revenue Next Year
- PCRX $11.66
- NMZ N/A
- P/E Ratio
- PCRX N/A
- NMZ N/A
- Revenue Growth
- PCRX 3.08
- NMZ N/A
- 52 Week Low
- PCRX $11.16
- NMZ $8.26
- 52 Week High
- PCRX $31.64
- NMZ $11.14
- Technical
- Relative Strength Index (RSI)
- PCRX 49.37
- NMZ 46.08
- Support Level
- PCRX $25.33
- NMZ $10.19
- Resistance Level
- PCRX $26.44
- NMZ $10.45
- Average True Range (ATR)
- PCRX 0.91
- NMZ 0.11
- MACD
- PCRX -0.03
- NMZ -0.00
- Stochastic Oscillator
- PCRX 61.96
- NMZ 48.75
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The company's investment objectives is to provide current income exempt from regular federal income tax by investing predominantly in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories. It seeks to provide attractive monthly tax-free income, portfolio diversification and attractive after tax total returns. The fund invests in municipal securities that are exempt from federal income taxes.